Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety.
Schrödinger: Still Waiting On A Catalyst
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing.
Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Kyle Yang - Jefferies CJ Yeh - Leerink Partners Brendan Smith - TD Cowen Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Malcolm Hoffman - BMO Capital Markets Matt Hewitt - Craig-Hallum Capital Group Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's conference call to review Fourth Quarter and Full Year 2024 Financial Results.
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Schrodinger price target raised to $28 from $27 at Goldman Sachs
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company's Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note. Schrodinger -0.165 (-0.74%) Novartis -1.08 (-1.03%)
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call.
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results.
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.
